Candel Therapeutics (CADL) Non Operating Income (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Non Operating Income data on file, last reported at -$13.7 million in Q4 2025.

• For the quarter ending Q4 2025, Non Operating Income fell 131.69% year-over-year to -$13.7 million; the trailing twelve-month figure through Dec 2025 stood at $10.1 million (up 146.24% YoY), and the FY2025 full-year result was $10.1 million, up 146.24% from the prior year.
• Non Operating Income eased to -$13.7 million in Q4 2025, from $1.9 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $15.5 million in Q1 2025 to a low of -$13.7 million in Q4 2025.
• A 5-year average of -$287000.0 and a median of $186000.0 in 2021 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income sank 38945.71% in 2024 and surged 4961.76% in 2025, its largest moves.
• Tracing CADL's Non Operating Income over 5 years: stood at $9.3 million in 2021, then tumbled by 67.67% to $3.0 million in 2022, then plunged by 125.75% to -$777000.0 in 2023, then slumped by 663.45% to -$5.9 million in 2024, then sank by 131.69% to -$13.7 million in 2025.
• Business Quant data shows CADL's Non Operating Income at -$13.7 million in Q4 2025, $1.9 million in Q3 2025, and $6.4 million in Q2 2025.